M2e, human TFA

Cat. No.: HY-P1783A

Molecular Formula: $C_{109}H_{171}F_3N_{32}O_{43}S_2$

Molecular Weight: 2738.83

Sequence: Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Ile-Arg-Asn-Glu-Trp-Gly-Cys-Arg-Cys-Asn-Asp-Ser-Ser-Asp SLLTEVETPIRNEWGCRCNDSSD (TFA salt)

Sequence Shortening: SLLTEVETPIRNEWGCRCNDSSD

Target: Influenza Virus

Pathway: Anti-infection

Storage: Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (36.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.3651 mL	1.8256 mL	3.6512 mL
	5 mM	0.0730 mL	0.3651 mL	0.7302 mL
	10 mM	0.0365 mL	0.1826 mL	0.3651 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A[1].

REFERENCES

[1]. De Filette M, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine. 2006 Nov 10;24(44-46):6597-601.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA